The case for & against
Bull & Bear analysis
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) is an emerging biopharmaceutical company focused on developing innovative treatments for recurrent Clostridioides difficile infections (R-CDI) and acute CDI, primarily through its lead antibiotic candidate, Ibezopulstat. Positioned within the growing antimicrobial sector, Acurx aims to address critical public health needs exacerbated by antibiotic resistance, targeting high recurrence rates associated with existing treatments. The company holds an advantageous position as its product pipeline is driven by strong clinical data and favorable regulatory support, including QIDP and Fast Track designations from the FDA.
Bull says
- ↑96% cure rate in Phase II Ibezopulstat trials suggests strong efficacy.
- ↑Cash balance rose to $9.3M from $7.6M in Q1 2026.
- ↑R&D expenses halved to $0.3M YoY, boosting runway.
- ↑U.S. CDI market ~$5B annually; $2.8B in recurrent cases.
- ↑New patents and FDA Fast Track/QIDP designations enhance IP moat.
- ↑Positive factor exposures: high book-to-price ratio and liquidity.
Bear says
- ↓Negative profitability metrics hinder ability to generate returns.
- ↓Net loss narrowed to $1.7M but cash burn remains.
- ↓Potential dilution risk as future funding needs grow.
- ↓Regulatory shifts may delay antibiotic approval timelines.
- ↓Competition from Merck, Pfizer, Seres threatens market share.
- ↓High short interest reflects bearish investor sentiment.
Earnings Call · Q1 2025 · Mgmt. Guidance
Transcript signals
Bull points
- positive regulatory guidance from the European Medicines Agency for the Adventist Full-Step Phase 3 Clinical Trial Program, which is aligned with FDA on matters of manufacturing, non-clinical, and clinical aspects of the Phase 3 program.
- Looking forward to the weeks ahead, I can share with you that our outstanding faith to clinical trial data has been accepted for publication in the premier medical journal, Lancet Micro, and is now in press to be published shortly and summarizes abeziflofab's safety results, as follows, and I quote, results include a high rate of clinical cure in abeziflofab-treated subjects with no recurrence. Furthermore, abeziflofab is proud to be safe, well-tolerated, and associated with the preservation of key health-promoting bacteria responsible for bile acid homeostasis, a key component in preventing refrained CDIs.
- The company ended the quarter with cash totaling $4.6 million, compared to $3.7 million as of December 31, 2024.
Bear points
- I don't want to provide a hypothetical date for the start of Phase 3 because we don't have the funding yet, and if we don't make the decision on the other side of where that funding is coming from, it's kind of hard to predict.
- I don't want to provide a hypothetical date for the start of Phase 3 because we don't have the funding yet, and if we don't make the decision on the other side of where that funding is coming from, it's kind of hard to predict.
- The company reported a net loss of $2.1 million, or 11 cents per diluted share, for the three months ended March 31, 2025, compared to a net loss of $4.4 million, or $0.28 per diluted share, for the three months ended March 31, 2024.